

## P&T Motion History Atopic Dermatitis

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<b>abrocitinib</b> <b>azathioprine</b> crisaborole <b>cyclosporine</b> dupilumab <b>mycophenolate</b> <b>omalizumab</b> pimecrolimus <b>ruxolitinib</b> tacrolimus <b>tralokinumab</b> <b>upadacitinib</b>	After considering the evidence of safety, efficacy and special populations for the treatment of Atopic Dermatitis, I move that abrocitinib, azathioprine, crisaborole, cyclosporine, dupilumab, mycophenolate, omalizumab, pimecrolimus, ruxolitinib, tacrolimus, tralokinumab, and upadacitinib are safe and efficacious for the treatment of their approved indications. The calcineuran inhibitors can be subject to therapeutic interchange in the Washington preferred drug list.  Motion: Flatebo 2 <sup>nd</sup> : Buccola	February 16, 2022	NA	No	Passed unanimous